Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    INmune Bio Inc.

    NASDAQ: INMB · Real-Time Price · USD
    7.61
    0.26 (3.54%)
    At close: Jun 06, 2025, 3:59 PM
    7.57
    -0.53%
    After-hours: Jun 06, 2025, 05:14 PM EDT

    INmune Bio Statistics

    Share Statistics

    INmune Bio has 23.21M shares outstanding. The number of shares has increased by 34.42% in one year.

    Shares Outstanding

    n/a
    		 23.21M

    Shares Change (YoY)

    n/a
    		 34.42%

    Shares Change (QoQ)

    n/a
    		 19.93%

    Owned by Institutions (%)

    n/a
    		 30.57%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 8,003

    FTD / Avg. Volume

    n/a
    		 2.89%

    Short Selling Information

    The latest short interest is 5.87M, so 25.29% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.87M

    Short % of Shares Out

    n/a
    		 25.29%

    Short % of Float

    n/a
    		 31.41%

    Short Ratio (days to cover)

    n/a
    		 25.21

    Valuation Ratios

    The PE ratio is -2.21 and the forward PE ratio is -4.53. INmune Bio's PEG ratio is -0.09.

    PE Ratio

    n/a
    		 -2.21

    Forward PE

    n/a
    		 -4.53

    PS Ratio

    n/a
    		 6652.85

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 2.9

    P/FCF Ratio

    n/a
    		 -2.79

    PEG Ratio

    n/a
    		 -0.09
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for INmune Bio.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 3.14

    Quick Ratio

    n/a
    		 3.14

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,076.92

    Profits Per Employee

    n/a
    		 $-3,237,076.92

    Employee Count

    n/a
    		 13

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -17.54% in the last 52 weeks. The beta is 1.57, so INmune Bio's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.57

    52-Week Price Change

    n/a
    		 -17.54%

    50-Day Moving Average

    n/a
    		 7.52

    200-Day Moving Average

    n/a
    		 6.68

    Relative Strength Index (RSI)

    n/a
    		 47.69

    Average Volume (20 Days)

    n/a
    		 276,601

    Income Statement

    In the last 12 months, INmune Bio had revenue of 14K and earned -42.08M in profits. Earnings per share was -2.08.

    Revenue

    n/a
    		 14K

    Gross Profit

    n/a
    		 14K

    Operating Income

    n/a
    		 -42.63M

    Net Income

    n/a
    		 -42.08M

    EBITDA

    n/a
    		 -42.08M

    EBIT

    n/a
    		 -42.63M

    Earnings Per Share (EPS)

    n/a
    		 -2.08
    Full Income Statement

    Balance Sheet

    The company has 20.92M in cash and 384K in debt, giving a net cash position of 20.54M.

    Cash & Cash Equivalents

    n/a
    		 20.92M

    Total Debt

    n/a
    		 384K

    Net Cash

    n/a
    		 20.54M

    Retained Earnings

    n/a
    		 -163.1M

    Total Assets

    n/a
    		 37.8M

    Working Capital

    n/a
    		 13.03M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -33.36M and capital expenditures 0, giving a free cash flow of -33.36M.

    Operating Cash Flow

    n/a
    		 -33.36M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -33.36M

    FCF Per Share

    n/a
    		 -1.67
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -304535.71% and -300585.71%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -304535.71%

    Pretax Margin

    n/a
    		 -300585.71%

    Profit Margin

    n/a
    		 -300585.71%

    EBITDA Margin

    n/a
    		 -300585.71%

    EBIT Margin

    n/a
    		 -304535.71%

    FCF Margin

    n/a
    		 -238292.86%

    Dividends & Yields

    INMB does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for INMB is $23, which is 211.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $23

    Price Target Difference

    n/a
    		 211.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 2.34

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist